Merck announced the expansion of its high-potent active pharmaceutical ingredient (HPAPI) and antibody-drug conjugate (ADC) production capabilities and capacity at…
Construction of the Scientia Clinical Research (SCR) facility at the Randwick Hospitals campus in the University of New South Wales (UNSW) began in November 2014.
The facility will accommodate early phase clinical trials to provide a full-range of specialities in cancer, ophthalmology, neurology, addiction medicine, rheumatology and paediatrics.
It will also provide investigation of medicines, biomedical equipment, devices and other procedures and treatments.
The clinical research facility is being constructed under stage two of Nelune Comprehensive Cancer Centre (NCCC) and Scientia Clinical Research (SCR) project as a member of the Bright Alliance, a partnership between Prince of Wales Hospital and UNSW Australia.
The Department of Planning and Environment gave planning approval for stage two of the building construction on 15 May 2014. The SCR facility is expected to be ready for operations by mid-2016.
Scientia clinical research facility details
Scientia Clinical Research (SCR) facility will be part of the ten level stage two building. It will be collocated within a major research precinct that includes the NCCC, the Prince of Wales Hospital and the Lowy Cancer Research Centre.
The research centre will provide services to the biotechnology and the pharmaceutical industry. It will perform phase I to IV clinical trials for multinational and national pharmaceutical and biotechnology companies, as well as support small and medium trials initiated by co-operative trial groups and research investigators.
It will be connected to the Prince of Wales Hospital, Royal Hospital for Women and Sydney Children’s Hospital through links at levels one and two of the building.
Project benefits of the clinical research facility
The facility will promote New South Wales (NSW) as a prime location for clinical trials and provide an opportunity for fast tracking new medical discoveries. It will help to bridge the gap between cancer patients, cancer services and basic and translational researchers.
It will also offer advice and assistance to academic researchers and clinicians on the design and conduct of clinical research.
The facility will provide benefits by enhancing skills and knowledge of clinical researchers and ancillary staff, and support better outcomes for patients by improving clinical standards. It will further provide opportunities for patients to be included in clinical trials, establish a support network for researchers to increase trial activity and share ideas.
In addition, the facility will improve research revenue to support funding of the local research infrastructure.
The Lowy Cancer Research Institute, located on the premises of University of New South Wales (UNSW), Sydney, is the largest dedicated cancer research centre in southern Australia.
The SCR facility is estimated to be completed with an investment of $23.8m. It is jointly financed through the Therapeutic Innovation Australia and by the NSW State Government.
Stage two construction details
Stage two of the bigger project includes demolition of the existing radiation oncology building and construction of the new NCCC, SCR facility and Sydney Children’s Hospitals Network levels. Bulk excavation works for the project were completed by May 2015.
The first stage of project construction started in 2012 and was completed in November 2014. It included construction of a new lower ground treatment area, including four radiotherapy bunkers, with three linear accelerators and connections from the radiotherapy treatment area to Prince of Wales Hospital.
A W Edwards was awarded the contract to provide construction services for stage two. Johnstaff, as project manager, will provide design development, contract documentation, administration, health planning, procurement and commissioning for the project.
Thermo Fisher Scientific opened a new manufacturing facility in Lenexa, Kansas to meet the increasing demand for viral transport media…
Bushu Pharmaceuticals unveiled a new expansion programme for its pharmaceutical manufacturing facility in Misato, Japan, in August 2020. With the…
Contract development and manufacturing organisation (CDMO) Sai Life Sciences inaugurated its new research and technology (R&T) centre in Hyderabad, India…